Skip to content

WellCareChina

Independent medical information for international patients

Menu

Disease

Cervical cancer宫颈癌

ICD-10: C53 — Malignant neoplasm of cervix uteri

Group: Cancer Specialty: Gynecology

Key figures

Published values only. Every tile opens the section that carries its source, its year and its caliber.

Disease details

Standard Chinese name
宫颈癌
English name
Malignant neoplasm of cervix uteri

Values written in Chinese are quoted as published by the source.

Also known as

  • Cervical cancer
  • CC

Treatment cost ranges

Every range below is published on one billing basis: Pre-reimbursement 医保报销前. The sources publish no post-reimbursement figure, so none is shown here.

Treatment path Cost range Price basis Data year
Surgery 手术 30000 – 35530 CNY Condition package price 病种打包全包价 2020–2025
Radiotherapy 放疗 45000 – 57000 CNY Per-item price 项目价 2025–2026
Chemotherapy 化疗 30000 – 64000 CNY Average per case (full course) 全病程例均 2022–2023
Targeted therapy 靶向 88000 – 177000 CNY Per-item price 项目价 2025
Immunotherapy 免疫 145080 – 193440 CNY Per-item price 项目价 2025

The bars share one scale across the rows above: each starts at that row's lower published figure and ends at its upper one. The highest upper figure on this page is 193440 CNY. Each row keeps its own data year and caliber.

5 cost ranges for this condition, each with its source on the row page.

Values written in Chinese are quoted as published by the source.

See all cost ranges →

Five-year survival

5-year survival rate 66.9% 95% CI 66.5–67.4

Population
Overall (all stages combined) · Age-standardised relative survival 总体（全分期合并）· 年龄标准化相对生存率
Period
2019–2021
Publisher
National Cancer Center 国家癌症中心
Value nature
Estimated value (hybrid analysis) 估计值（混合法）
Registry scope
281 population-based cancer registries 281 个肿瘤登记处
Stage data availability
Not published

Values written in Chinese are quoted as published by the source.

See all survival rates →

How to read this figure. It is published for all stages combined, so it is an average over everyone in the national registry data rather than a prognosis for one person. For most cancers, the stage at diagnosis is the strongest single factor behind survival differences: survival is generally higher when the cancer is found at an earlier stage and lower when it is found later. Comparisons between cancers are also shaped by how early or late each one tends to be diagnosed, so a lower figure does not by itself mean worse care.

Hospitals with a published record for this condition

Selected using official public data sources

These hospitals are selected from official public data sources — the Fudan University hospital specialty reputation rankings, the national key clinical specialties list and national clinical research centres — so each line on a card can be checked against its published source. This is not a paid or promoted listing.

How these hospitals were selected

Admission. A hospital is listed for a condition when the specialty that condition is filed under carries at least one of: a place or a nomination in the Fudan University hospital specialty reputation ranking; a national key clinical specialty record at level A, B or C; or a national clinical research centre or a state key laboratory in that specialty. JCI accreditation is shown as a badge; it never decides admission and it never decides order.

Order. Step 1: a Fudan place between 1 and 10 for the specialty. Step 2: another Fudan place, or a nomination. Step 3: a level-A national key clinical specialty. Step 4: a level-B national key clinical specialty. Step 5: a national clinical research centre or a state key laboratory in the specialty, a centre before a laboratory. Step 6: a level-C national key clinical specialty, which is a record we publish without an independent official source and which is therefore listed after the others.

Ties. Within one step: the better Fudan place first, then the stronger key-specialty level (A before B before C), then the province, then the city, then the hospital name - the same province-city-name order the hospital directory uses. At most eight hospitals are listed.

When the list is short. Five hospitals or more: the first eight are listed. Three or four: all of them are listed, and a further fold adds the remaining records up to eight, each carrying its evidence level. One or two: the same, with that fold open and a line stating how many hospitals have a strong public record. None: the page states that no strong public record was found and links to the specialty directory. A place, an institution or a count is never invented to fill the list.

The Fudan rankings are the hospital specialty reputation ranking most widely recognised by Chinese clinicians, published annually by Fudan University's hospital management institute.

  1. Peking Union Medical College Hospital中国医学科学院北京协和医院

    Dongcheng District 东城区

    Fudan specialty reputation ranking 2023

    Research platform

    Also ranked: General Surgery #1, Urology #8, Otorhinolaryngology #4 in the Fudan list.

  2. Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology华中科技大学同济医学院附属同济医院

    Wuhan 武汉市

    Fudan specialty reputation ranking 2023

    National key clinical specialty

    Research platform

    Also ranked: General Surgery #6, Urology #5, Respiratory Medicine #8 in the Fudan list.

  3. Obstetrics and Gynecology Hospital of Fudan University复旦大学附属妇产科医院

    Shanghai 上海市

    Fudan specialty reputation ranking 2023

    National key clinical specialty

    Published research

    10 more published studies

    PubMed indexes 12 papers on this condition that name this hospital.

  4. Peking University Third Hospital北京大学第三医院

    Beijing 北京市

    Fudan specialty reputation ranking 2023

    National key clinical specialty

    Research platform

    Also ranked: Urology nominated, Gastroenterology nominated, Respiratory Medicine nominated in the Fudan list.

  5. Women's Hospital, School of Medicine, Zhejiang University浙江大学医学院附属妇产科医院

    Zhejiang 浙江省

    Fudan specialty reputation ranking 2023

    Published research

    5 more published studies

    PubMed indexes 7 papers on this condition that name this hospital.

  6. West China Second University Hospital, Sichuan University四川大学华西第二医院

    Chengdu 成都市

    Fudan specialty reputation ranking 2023

    National key clinical specialty

  7. Qilu Hospital of Shandong University山东大学齐鲁医院

    Jinan 济南市

    Fudan specialty reputation ranking 2023

    National key clinical specialty

    Published research

    PubMed indexes 1 paper on this condition that names this hospital.

    Also ranked: Otorhinolaryngology nominated, Gastroenterology nominated in the Fudan list.

  8. Peking University People's Hospital北京大学人民医院

    Beijing 北京市

    Fudan specialty reputation ranking 2023

    National key clinical specialty

    Published research

    PubMed indexes 1 paper on this condition that names this hospital.

    Also ranked: General Surgery #10, Thoracic Surgery #7, Otorhinolaryngology nominated in the Fudan list.

Clinical trials (investigational treatments)

In addition to standard care, clinical research studies for Cervical cancer may currently be open to participants in China. The treatments under study have not been approved by the regulator as standard therapy — they are clinical research, not routine treatment. Each record names the lead investigator and the hospital running the study. If you are interested, contact the hospital to ask about eligibility and choose whether to apply.

  1. Study Randomized Controlled Trial of the Efficacy of Adjuvant Chemotherapy in Patients With Residual Lesions After Concurrent Radiochemotherapy for Locally Advanced Cervical Cancer

    Lead investigator
    Dongling Zou · Associated Director
    Hospital
    Chongqing University Cancer Hospital
    Status
    Recruiting
    Registry
    NCT04409860

  2. Study Induction Immunotherapy Combined With Chemotherapy Followed by Concurrent Chemoradiotherap and Immunotherapy for Advanced Cervical Cancer: An Open-Label, Single-Arm, Phase II Trial

    Hospital
    Tianjin Medical University Cancer Institute & Hospital
    Status
    Recruiting
    Registry
    NCT07092696

  3. Study A Study of Efbemalenograstim Alfa Injection for Ovarian or Cervical Cancer Receiving Chemotherapy Regimen With Risk Factors:A Single-Arm, Multicenter Clinical Trial

    Lead investigator
    Beihua Kong · Clinical Professor
    Hospital
    Xiangya Hospital of Central South University
    Status
    Recruiting
    Registry
    NCT06251947

  4. Study Clinical Study on Optimization of Postoperative Adjuvant Therapy for Cervical Cancer Based on MRD

    Lead investigator
    jing xue · Associate chief physician
    Hospital
    Suzhou Municipal Hospital
    Status
    Recruiting
    Registry
    NCT05872724

  5. Study Para-aortic Prophylactic Irradiation for Locally Advanced Cervical Cancer: a Prospective, Randomized, Multicenter Study

    Hospital
    Zhejiang Cancer Hospital
    Status
    Recruiting
    Registry
    NCT04974346
25 more registered studies

  1. Study Camrelizumab Combined With Chemotherapy for Adjuvant Treatment of Cervical Cancer Patients With Pathologically Confirmed Lymph Node Positivity After Stage Surgery: A Prospective, Single-Arm, Multicenter, Phase II Clinical Trial

    Hospital
    Women's Hospital, School of Medicine, Zhejiang University
    Status
    Recruiting
    Registry
    NCT07167160

  2. Study Development and Validation of a CT-Based Radiomics Nomogram for the Prediction of Postoperative Malnutrition in Stage IB1-IIA2 Cervical Cancer (Nutrition Helper-1).

    Lead investigator
    Tao Song, MD · Attending Doctor
    Hospital
    Zhejiang Provincial People's Hospital
    Status
    Recruiting
    Registry
    NCT05709769

  3. Study Randomized Controlled Trial of the Efficacy of Lymph Node Dissection on Stage IIICr of Cervical Cancer

    Lead investigator
    Dongling Zou · Director of Gynecologic Oncology Department
    Hospital
    Chongqing University Cancer Hospital
    Status
    Recruiting
    Registry
    NCT04555226

  4. Study A Single-arm, Multicenter, Phase II Study to Evaluate Cadonilimab（AK104） Combined With Radiotherapy For The Treatment of Locally Advanced Cervical Cancer

    Lead investigator
    Qi Zhou · Professor
    Hospital
    Chongqing University Cancer Hospital
    Status
    Recruiting
    Registry
    NCT05687851

  5. Study Non-randomized Concurrent Controlled Trial of Surgery Staging or Image Staging of Locally Advanced Cervical Cancer

    Lead investigator
    Dongling Zou · Director of Gynecologic Oncology Department
    Hospital
    Chongqing University Cancer Hospital
    Status
    Recruiting
    Registry
    NCT05378087

  6. Study Stored Hematopoietic Stem Cell-containing Autologous Blood Transfusion Therapy for Bone Marrow Protection in Patients With Cervical Cancer Treated With Concurrent Chemoradiotherapy

    Hospital
    Chongqing University Cancer Hospital
    Status
    Recruiting
    Registry
    NCT05401175

  7. Study Salvage Surgery for Patients With Residual Disease After Concurrent Chemoradiation Therapy for Locally Advanced Cervical Cancer: A Prospective, Single-arm Clinical Study.

    Lead investigator
    Dongling Zou · Director of Gynecologic Oncology Department
    Hospital
    Chongqing University Cancer Hospital
    Status
    Recruiting
    Registry
    NCT05749887

  8. Study Exploratory Study on Near-Infrared Fluorescence Imaging Technology Combined with Indocyanine Green Guided Cervical Cancer Lymph Node Metastasis

    Hospital
    Obstetrics and Gynecology Hospital of Fudan University
    Status
    Recruiting
    Registry
    NCT06840418

  9. Study Neoadjuvant Chemotherapy Plus Camrelizumab (NACI Therapy) for Fertility Preservation in FIGO Stage IB1 Cervical Cancer

    Lead investigator
    Kezhen Li · Prof
    Hospital
    Sun Yat-sen Memorial Hospital, Sun Yat-sen University
    Status
    Recruiting
    Registry
    NCT06289062

  10. Study Evalutaion of the SNPs Test in Average Cervical Cancer Screening Episode

    Hospital
    First Affiliated Hospital of Guangzhou Medical University
    Status
    Recruiting
    Registry
    NCT06405945

  11. Study Disitamab Vedotin Combined With Cisplatin for Neoadjuvant Therapy in Locally Advanced Cervical Cancer: a Prospective, Single-arm Clinical Trial

    Lead investigator
    Kun Song · Chief Physician
    Hospital
    Qilu Hospital of Shandong University
    Status
    Recruiting
    Registry
    NCT06558682

  12. Study A Multicenter, Non-inferiority Trial to Compare the Effectiveness and Safety of Laparoscopic Radical Hysterectomy Incorporating Modified Tumor-free Techniques Versus Abdominal Radical Hysterectomy in Patients With Stage IB2 Cervical Cancer

    Lead investigator
    xiang yang
    Status
    Recruiting
    Registry
    NCT06836869

  13. Study A Prospective, Randomized, Parallel-Controlled Clinical Study of Nanocrystalline Megestrol Acetate in Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer

    Lead investigator
    Jingjing Wang · associate chief physician
    Hospital
    Second Xiangya Hospital of Central South University
    Status
    Recruiting
    Registry
    NCT07338487

  14. Study Neoadjuvant Chemotherapy Plus Cadonilimab for Locally Advanced Cervical Cancer : a Multicentre, Single Arm, Phase 2 Trial

    Lead investigator
    Xie Ya · Professor
    Hospital
    First Affiliated Hospital of Zhengzhou University
    Status
    Recruiting
    Registry
    NCT07104149

  15. Study A Single-Arm Exploratory Study of Enlansibumab Sequentially Combined With Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer

    Hospital
    Chongqing University Cancer Hospital
    Status
    Not yet recruiting
    Registry
    NCT06981858

  16. Study A Single-Center, Single-Arm, Phase II Study of Perioperative Adebrelimab Combined With Neoadjuvant Paclitaxel and Platinum Chemotherapy in Locally Advanced Cervical Cancer

    Hospital
    Anhui Provincial Hospital
    Status
    Not yet recruiting
    Registry
    NCT07811375

  17. Study Neoadjuvant Ivonescimab Combined With Paclitaxel and Cisplatin, Followed by Concurrent Chemoradiotherapy in Patients With High-Risk Locally Advanced Cervical Cancer：A Phase II, Single-Arm Study

    Hospital
    Women's Hospital, School of Medicine, Zhejiang University
    Status
    Not yet recruiting
    Registry
    NCT07244965

  18. Study A Single-arm Exploratory Clinical Study of Envafolimab With Chemoradiotherapy for Women With Locally Advanced Cervical Cancer

    Lead investigator
    Qi Zhou · Professor
    Hospital
    Chongqing University Cancer Hospital
    Status
    Not yet recruiting
    Registry
    NCT05799469

  19. Study A Multi-Center Phase II Clinical Study of Camrelizumab Combined With Famitinib Malate and Platinum-based Chemotherapy in the Treatment of Recurrent/Metastatic Cervical Cancer

    Hospital
    Hunan Cancer Hospital
    Status
    Not yet recruiting
    Registry
    NCT07627620

  20. Study ctDNA-guided First-line Immuno-de-escalation Therapy for Stage IVB and Recurrent Cervical Cancer: A Prospective, Single-arm, Multicenter Phase II Clinical Trial

    Hospital
    Obstetrics and Gynecology Hospital of Fudan University
    Status
    Not yet recruiting
    Registry
    NCT06878196

  21. Study A Prospective Cohort Study Comparing Artificial Intelligence Multimodal Fusion Prediction Models With Conventional Imaging Assessment for the Diagnosis of Pelvic Lymph Node Metastasis in Cervical Cancer

    Lead investigator
    Xin Wu · Deputy Chief of Gynecologic Oncology
    Hospital
    Obstetrics and Gynecology Hospital of Fudan University
    Status
    Not yet recruiting
    Registry
    NCT06541288

  22. Study Utidelone Combined With Toripalimab in Patients With Pretreated Recurrent or Metastatic Cervical Cancers: a Single-Arm, Phase II Study

    Lead investigator
    Hui Qiu · Head of Department
    Hospital
    Zhongnan Hospital of Wuhan University
    Status
    Not yet recruiting
    Registry
    NCT07363330

  23. Study Real-World Effectiveness and Safety of Iparomlimab and Tuvonralimab in Recurrent or Metastatic Cervical Cancer: A Target Trial Emulation Study

    Hospital
    Qilu Hospital of Shandong University
    Status
    Not yet recruiting
    Registry
    NCT07652983

  24. Study A Single-arm, Multicenter, Phase II Clinical Study of Camrelizumab Combined With Famitinib in Adjuvant Therapy After Radical Resection of Cervical Cancer

    Lead investigator
    Jin LI · Principal Investigator
    Hospital
    Fudan University Shanghai Cancer Center
    Status
    Not yet recruiting
    Registry
    NCT07466901

  25. Study AK104 Combined With Iodine-125 Brachytherapy in the Treatment of Recurrent or Metastatic Cervical Cancer

    Hospital
    Peking University Third Hospital
    Status
    Not yet recruiting
    Registry
    NCT06062589

This page only shares publicly registered study information. It does not recommend or encourage joining any study. Participation is entirely voluntary and the risks of an unapproved treatment are unknown; contact the hospital directly for eligibility and informed-consent details.

Hospitals with a national key specialty record

Show the hospital records 25 hospitals with a key-specialty record

Each row is a hospital with a national key clinical specialty record in a specialty this condition is filed under. This is a record of published listings, not a recommendation and not a ranking.

Hospital City Specialty (as published) Evidence Source
Shanghai General Hospital上海市第一人民医院 Shanghai 上海市 Gynecology 妇产临床医学中心 Level B https://www.firsthospital.cn/List/Depart/f0
Obstetrics and Gynecology Hospital of Fudan University复旦大学附属妇产科医院 Shanghai 上海市 Gynecology 妇科 Level B https://www.fckyy.org.cn/news/info/id/361.shtml
China-Japan Friendship Hospital中日友好医院 Beijing 北京市 Gynecology 妇产科 Level B https://www.zryhyy.com.cn/zryh/c100020/202309/47e8245aa93343baac89762d4e80580f.shtml
Peking University People's Hospital北京大学人民医院 Beijing 北京市 Gynecology 妇科 Level B https://www.pkuph.cn/news_details/26715.html
Peking University First Hospital北京大学第一医院 Beijing 北京市 Gynecology 妇产科（妇科、产科） Level B https://www.pkufh.com/Html/News/Articles/64494.html
Peking University Third Hospital北京大学第三医院 Beijing 北京市 Gynecology 妇产科 · Gynecology 妇科 Level B https://www.puh3.net.cn/yygk/zdxk.htm
West China Second University Hospital, Sichuan University四川大学华西第二医院 Chengdu 成都市 Gynecology 妇科 · Gynecology 妇科肿瘤全程化诊治能力提升体系及创新转化平台建设 · Gynecology 妇科（妇科恶性肿瘤多学科诊疗平台建设） Level A https://wcums.scu.edu.cn/kxyan_jiu/gjlczdzk.htm
Anhui Provincial Hospital中国科学技术大学附属第一医院（安徽省立医院） Hefei 合肥市 Gynecology 妇产科 （含妇科） Level B https://www.ahslyy.com.cn/nanqu/col456/892156
The First Affiliated Hospital of Anhui Medical University安徽医科大学第一附属医院 Hefei 合肥市 Gynecology 妇产科 （含妇科） Level B https://www.ayfy.com/info/1184/27750.htm
The Second Hospital of Shandong University山东大学第二医院 Jinan 济南市 Gynecology 妇科 Level A http://wsjkw.shandong.gov.cn/wmfw/cxfw/202307/P020230717441794577839.xlsx
Qilu Hospital of Shandong University山东大学齐鲁医院 Jinan 济南市 Gynecology 妇科 Level A http://wsjkw.shandong.gov.cn/wmfw/cxfw/202307/P020230717441794577839.xlsx
Shandong Provincial Hospital山东省立医院 Jinan 济南市 Gynecology 妇科 Level A http://wsjkw.shandong.gov.cn/wmfw/cxfw/202307/P020230717441794577839.xlsx
Sun Yat-sen Memorial Hospital, Sun Yat-sen University中山大学孙逸仙纪念医院 Guangzhou 广州市 Gynecology 妇科 Level B https://www.gzsys.org.cn/basic/453
The First Affiliated Hospital, Sun Yat-sen University中山大学附属第一医院 Guangzhou 广州市 Gynecology 妇科 Level B https://gcp.fahsysu.org.cn/sites/1h.gcp.sysucloud1.sysu.edu.cn/files/2023-07/20230625%20中山大学附属第一医院宣传折页%20V5.0_0.pdf
Nanfang Hospital南方医科大学南方医院 Guangzhou 广州市 Gynecology 妇科 Level B https://www.nfyy.com/index.html
Guangdong Provincial People's Hospital广东省人民医院 Guangzhou 广州市 Gynecology 妇科 Level B https://www.gdghospital.org.cn/comprehensivenews/info_itemid_57420.html
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology华中科技大学同济医学院附属协和医院 Wuhan 武汉市 Gynecology 妇产科 Level B https://www.whuh.com/kxyj/xkjs/gjlczdzk/2.htm
Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology华中科技大学同济医学院附属同济医院 Wuhan 武汉市 Gynecology 妇科 Level B https://www.tjh.com.cn/contents/934/27291.html
Central Hospital of Wuhan武汉市中心医院 Wuhan 武汉市 Gynecology 妇产科 Level B https://zxhospital.com/gcp/info/1031/1548.htm
Third Xiangya Hospital中南大学湘雅三医院 Changsha 长沙市 Gynecology 妇科 Level B https://www.xy3yy.com/ksjj/184173.html
Shengjing Hospital中国医科大学附属盛京医院 Shenyang 沈阳市 Gynecology 妇科 Level B https://www.sj-hospital.cn/article/80.html
Liaoning Cancer Hospital辽宁省肿瘤医院 Shenyang 沈阳市 Gynecology 妇科 Level B https://www.lnchi.org.cn/ch/hospital/biref/index.html
Chongqing University Cancer Hospital重庆大学附属肿瘤医院 Chongqing 重庆市 Gynecology 妇科 Level A https://wsjkw.cq.gov.cn/zwgk_242/fdzdgknr/tzgg/gzgs/202405/t20240515_13209571.html
The First Affiliated Hospital of Xi'an Jiaotong University西安交通大学第一附属医院 Xi'an 西安市 Gynecology 妇科 Level B http://www.dyyy.xjtu.edu.cn/info/41461/122341.htm
The Second Affiliated Hospital of Xi'an Jiaotong University西安交通大学第二附属医院 Xi'an 西安市 Gynecology 妇科 Level B http://2yuan.xjtu.edu.cn/defsyy/xwzx1/yyyw_/4.htm

25 hospitals with a matching national key specialty record.

Values written in Chinese are quoted as published by the source.

Questions about this condition

We cannot give medical advice, but we can answer questions about this page and about arranging treatment in China.

Ask us about this condition

ICD codes

Show the code table 5 ICD codes
Version Code Name in that version
ICD-10-WHO C53 Malignant neoplasm of cervix uteri
ICD-10-WHO C53.0 Endocervix
ICD-10-WHO C53.1 Exocervix
ICD-10-WHO C53.8 Overlapping lesion of cervix uteri
ICD-10-WHO C53.9 Cervix uteri, unspecified

Rows are the WHO ICD-10 entries for this condition, quoted as published.

Source & evidence

Source URL
https://wjw.fujian.gov.cn/xxgk/fgwj/zxwj/201904/P020190412506737868905.xlsx
Source scheme
https
Source type
Provincial health commission
Evidence level
A - said by a provincial health commission or university
Retrieved on
2026-09-24